Hypertrophic Cardiomyopathy Market Report and Forecast 2025-2034

Hypertrophic Cardiomyopathy Market Size

The hypertrophic cardiomyopathy market was valued at USD 1.29 billion in 2024 driven by the advances in imaging technologies for early detection across the 8 major markets. The market is anticipated to grow at a CAGR of 3.50% during the forecast period 2025-2034 to reach a value of USD 1.76 billion by 2034.

Hypertrophic Cardiomyopathy Market Outlook

• The market value is influenced by the increasing integration of artificial intelligence into the diagnostic techniques for cardiology.

• The market demand is driven by the growing preference for minimally invasive procedures such as alcohol ablation due to reduced risk of complications and shorter recovery time.

• The rising number of clinical trials focused on hypertrophic cardiomyopathy is contributing to the introduction of novel therapies for the condition, likely to propel market growth in the forecast period.

Hypertrophic Cardiomyopathy Market Overview

Hypertrophic cardiomyopathy (HCM) is a common genetic cardiovascular disease. It is generally caused by abnormal genes in the heart muscle due to which the heart muscle becomes thick, making it hard for the heart to pump blood properly. Hypertrophic cardiomyopathy is likely to be underdiagnosed clinically because of few to no symptoms.

Substantial investments in the development of advanced HCM therapies and diagnostics by pharmaceutical and biotech firms are contributing to the expansion of the hypertrophic cardiomyopathy market. Further, the rising demand for minimally invasive procedures such as alcohol ablation due to reduced risk of complications and shorter recovery time is expected to drive the hypertrophic cardiomyopathy market growth in the coming years.

Hypertrophic Cardiomyopathy Market Growth Drivers

Surge in Clinical Trials to Bring Potential Treatments

The market value is expected to be boosted by continuous clinical trials that potentially bring effective and advanced treatments for hypertrophic cardiomyopathy (HCM). In HCM, patients experience increased pressures in the heart due to obstructed blood flow leading to symptoms including chest pain, shortness of breath, and reduced exercise capacity. In May 2024, a phase 3 clinical trial showcased the positive effects of a cardiac myosin inhibitor called aficamten in patients with HCM. The inhibitor successfully reduced obstructed blood flow and enhanced the patient's ability to exercise. Such clinical trials with a positive impact on patients may potentially bring new treatments to the market and increase market value by bridging gaps of unmet needs in the treatment, propelling market growth.

Artificial Intelligence in Diagnostic Cardiology to Meet Hypertrophic Cardiomyopathy Market Demand

One of the major market trends is the rising integration of artificial intelligence in diagnostic cardiology. In August 2023, California-based software company Viz.ai’s hypertrophic cardiomyopathy artificial intelligence (AI) detection algorithm called the HCM module received De Novo approval from the US Food and Drug Administration. The company received financial aid from Bristol Myers Squibb (under a multi-year agreement) for the deployment of the AI-powered algorithm which can be integrated into the Viz.ai Platform. The approval established a new category for cardiovascular machine learning-based notification software. The Viz HCM module can identify suspected HCM cases by automatically reviewing routine electrocardiograms (ECGs) and subsequently notifying the healthcare providers on the Viz mobile application. Such advancements in diagnostic technology are expected to elevate the hypertrophic cardiomyopathy market value in the coming years.

Innovative Therapies Bolstering Market Demand
 
The market growth is also influenced by the increasing introduction of innovative therapies. In October 2023, Ohio-based non-profit academic medical centre Cleveland Clinic performed the world’s first-in-human gene therapy (TN-201) developed by Tenaya Therapeutics, Inc. to treat hypertrophic cardiomyopathy as part of a MyPeak-1 Phase 1b clinical trial. This one-time infusion therapy was given to a 27-year-old woman who is reported to be doing well. The trial, which is designed to assess the efficacy, safety, and tolerability of TN-201, is planning to enroll at least six symptomatic adults. The growth in such clinical studies is poised to support the development of novel treatments which will ultimately bolster the market growth.

Hypertrophic Cardiomyopathy Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Hypertrophic Cardiomyopathy Market Growth Segmentation

Market Breakup by Disease Type

• Obstructive

• Non-Obstructive

Market Breakup by Treatment Type

• Medication
  • Antiarrhythmic Agents
  • Anticoagulants
  • Beta Adrenergic Blocking Agents
  • Calcium Channel Blockers
  • Others

• Surgically Implanted Devices

• Nonsurgical Procedures

• Others

Market Breakup by End User

• Hospitals

• Research Institutes

• Specialty Clinics

• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

• India

Hypertrophic Cardiomyopathy Market Share

Segmentation by Treatment Type Leads the Market Share

The treatment type segment is expected to dominate the market share in the forecast period. Treatment types include medications, surgically implanted devices, and nonsurgical procedures, among others. Medications are further divided into antiarrhythmic agents, anticoagulants, beta-adrenergic blocking agents, and calcium channel blockers, among others. The medications are leading the market segment as the condition requires long-term treatment. The easy availability and cost-effectiveness of the medicines, increase the demand in the market, propelling market growth.

Hypertrophic Cardiomyopathy Market Analysis by Region

Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain) and the United Kingdom, Japan and India. The regional market share is dominated by the United States due to the substantial awareness of hypertrophic cardiomyopathy among people, contributing to the increasing number of diagnoses and hospital footfall. According to the Columbia University Department of Medicine, approximately 5.8 million people in the United States are affected by heart failure, with nearly 700,000 new cases being diagnosed each year. The robust healthcare infrastructure with advanced technologies and diagnostic facilities of the region is driving the market growth. The presence of key players and continuous research and development activities by them are poised to bring new therapeutics for the treatment of hypertrophic cardiomyopathy, bolstering market value.

Leading players in the Hypertrophic Cardiomyopathy Market

The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:

Bayer AG

Bayer is a German pharmaceuticals and biotechnology company specialising in consumer health and crop science as well. The company’s pharmaceutical interests include developing therapeutics for oncology, cardiology, gynaecology, hematology, and ophthalmology.

Astra Zeneca Plc

AstraZeneca is a Swiss pharmaceuticals and biotechnology company with a portfolio including products for oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

 
Pfizer Inc.

Pfizer Inc., a leading research-based pharmaceutical and biomedical company, is involved in research and development activities to create drugs for hypertrophic cardiomyopathy and other cardiovascular diseases.

Gilead Sciences Inc.

Headquartered in California, Gilead is an American biopharmaceutical company focused on the development of antiviral drugs for the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Novartis AG 

Global medicine company Novartis International AG’s combination therapy Sacubitril and Valsartan is undergoing a Phase II trial for hypertrophic cardiomyopathy.

Other key players in the market include Viatris, CYTOKINETICS, and Bristol-Myers Squibb Company.

Key Highlights of the Report

Key Questions Answered in the Hypertrophic Cardiomyopathy Market

• What was the hypertrophic cardiomyopathy market value in 2023? 
• What is the hypertrophic cardiomyopathy market forecast outlook for 2025-2034? 
• What are the regional markets covered in the EMR report? 
• What is market segmentation based on disease type? 
• How is the market segmented based on treatment type? 
• Who are the end-users in the market? 
• What are the major factors aiding the hypertrophic cardiomyopathy market demand?  
• How has the market performed so far and how is it anticipated to perform in the coming years? 
• What are the market's major drivers, opportunities, and restraints?  
• Which regional market is expected to lead the market share in the forecast period?  
• Which country is expected to experience expedited growth during the forecast period?  
• What are the major hypertrophic cardiomyopathy market trends?
• Which treatment type is expected to dominate the market? 
• Which type will dominate the market share?  
• Which end-user will lead the market?
• Who are the key players involved in the hypertrophic cardiomyopathy market? 
• What is the patent landscape of the market? 
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?